idradenitis suppurativa (HS) is a potentially debilitating chronic inflammatory disease that has an impact on several quality-of-life domains.
There were 624 patients identified with 2 or more International Classification of Diseases, Ninth Revision (ICD-9), codes of 705.83 corresponding to HS between 2003 and 2013. Patients who were 18 to 64 years old at enrollment with at least 5 monitoring periods of 3 months' duration each were included in the analyses. We found 427 patients meeting inclusion criteria (Figure) . This cohort was validated by random medical record review of 55 cases which yielded a positive predictive value of 83.6% (95% CI, 70.7%-91.8%) using the case definition adopted by the Second International Conference on Hidradenitis Suppurativa; March 5, 2009 ; San Francisco, California.
Self-reported demographic information, tobacco smoking status, body mass index (BMI, calculated as weight in kilograms divided by height in meters squared), and highest category of treatment for HS were evaluated for each patient in 3-month time periods. The initial 3-month period was used to establish baseline smoking, obesity, and treatment status. Smoking status and BMI values were interpolated between periods in which no status was assessed. Smoking status was dichotomized as ever and never smokers. Obesity was defined as a calculated BMI of 30 or greater. In addition, we validated tobacco smoking and obesity in the cohort with separate regression analyses using diagnosis of respiratory disease (odds ratio [OR], 2.1; 95% CI, 1.1-4.2) and hypertension (OR, 2.2; 95% CI, 1.5-3.1), respectively, as outcomes. Treatments for HS were categorized as follows: 0, no treatment; 1, topical antiinflammatory or topical antibiotic regimens; 2, oral antibiotics; 3, oral retinoid; 4, immunomodulating agent; and 5, surgical management, excluding incision and drainage.
We used χ 2 tests to compare dichotomous variables that were reported as frequency possessing the trait. We constructed univariate and multivariate conditional logistic regression models using complete case series analysis to estimate odds of associated outcomes. Odds ratios, 95% CIs, and P values are reported. We used an a priori statistical significance level of 0.05. SAS statistical software was used to analyze the data (version 9.3; SAS Institute Inc).
Results
Patients with HS were monitored for a total of 6439 time periods, which equated to 1610 person-years for the analysis. The average monitoring time was 16.7 periods, or 4.2 personyears. Demographic and clinical characteristics for the HS cohort are outlined in Table 1 . The mean age of the HS treatment cohort was 39.4 years. The HS treatment cohort was composed mostly of women (74%) and was predominantly nonwhite (85%) patients. At the time of enrollment, less than half (45%) of these patients had engaged a dermatologist in their care. The frequency of ever being a tobacco smoker or ever being obese was 65% and 73%, respectively. Over the 4.2 person-years monitoring period, the frequency of patients with HS receiving no treatment reduced significantly, whereas the frequency of all treatment types increased significantly ( Table 2 ). The likelihood of receipt and escalation of treatment among patients with HS is described in Table 3 and Table 4 , respectively. In adjusted analysis, engaging a dermatologist (OR, 6.7; 95% CI, 5.2-8.6) provided the strongest predictor of having received treatment for HS, and it was also associated with increased odds of having escalated treatment (OR, 3.0; 95% CI, 2.4-3.7). While tobacco smoking had no association with receipt of treatment, it was associated with treatment escalation (OR, 1.4; 95% CI, 1.1-1.7). Obesity had no association with receipt or escalation of treatment.
Male sex was not associated with receipt or escalation of treatment. The likelihood of receiving (OR, 1.4; 95% CI, 1.2-1.8) or escalating treatment (OR, 1.2; 95% CI, 1.0-1.4) was increased between ages 18 to 39 years, compared with ages 40 to 64 years. Patients who self-identified as nonwhite (OR, 0.66; 95% CI, 0.46-0.94) were less likely to receive treatment, although race was not associated with treatment escalation. Having subsidized insurance was associated with an increased odds of receiving treatment (OR, 1.7; 95% CI, 1.5-2.1) as well as treatment escalation (OR, 1.2; 95% CI, 1.0-1.4). Number of physician visits was also associated with receipt and escalation of treatment. Greater number of visits increased the odds of receipt and escalation of treatment. Number of follow-up periods in the analysis had no association with receipt or escalation of treatment.
Discussion
During the study period, the frequency of patients with HS receiving no treatment decreased, while the frequency of their receiving any form of treatment increased. This may suggest that the natural course of disease involves increasing severity over time, prompting patients to seek treatment. Another explanation may be that patients frustrated with the course of even stable disease are troubled enough to pursue some form of treatment. Less than half of the patients in our cohort had engaged a dermatologist; however, this relationship was associated with the greatest likelihood of receiving treatment for HS. Moreover, care by a dermatologist also provided an increased likelihood that treatment for HS was escalated over time. Given that most patients with HS require some form of treatment, or in many instances advancement of treatment, quality of care and outcomes in these patients may be improved with early recognition of HS and referral to dermatology. While tobacco smoking had no greater influence on receipt of treatment among patients with HS, it was associated with treatment escalation. Tobacco smoking may either limit the effectiveness of treatment or lead to worsening of disease over time, both of which may require an escalation in treatment. The influence of tobacco smoking on treatment has not been explored previously. To date, the association between HS severity and tobacco smoking has been shown only through assessment via disparate scoring instruments, and the outcomes are controversial. In a Scandinavian cohort of 251 patients, tobacco smokers had a significantly higher median modified HS score compared with nonsmokers. 4 In a Dutch study, smoking pack-years was only modestly associated with HS severity as measured by the Hurley Stage. 5 French, Polish, and Olmstead County cohorts reported no significant association observed between tobacco smoking and HS severity, as assessed by Sartorius score or Hurley stage, in adjusted or multivariate analyses. [6] [7] [8] We observed no greater influence of obesity on either receipt or escalation of treatment among patients with HS. To our knowledge, the influence of obesity on point-of-care management has not been explored previously. Other observational studies have characterized the controversial relationship between obesity and HS severity as assessed by disparate scoring instruments. Increased BMI was independently associated with an increased median modified HS score in the Scandinavian cohort, 4 and an increased Sartorius score in the French cohort. 6 The Dutch study also showed a modest association between BMI and HS severity as measured by the Hurley stage. 5 However, no association was observed between BMI and Hurley stage among incident cases of HS in the Olmstead County cohort, 8 or among a smaller group of patients in a Polish cohort. 7 With limited evidence to guide treatment, and given that efficacy of treatment approaches have generally been suboptimal, dermatologists may adopt counseling on smoking cessation and weight loss as part of the therapeutic strategy. Overall, it important to recognize that disease or disease severity associations for HS with tobacco smoking and obesity are modest, remain controversial, and that no causal links have been established to date.
Secondary findings in this study may also relevant in developing short-and long-term treatment strategies. Patients with HS ages 18 to 30 years were more likely to receive and escalate treatment compared with those were 40 to 64 years old. Younger patients may be more likely to seek out treatment and be more aggressive in escalating treatment given the significant impact on quality of life associated with HS. However, this observation also may reflect onset and course of disease in HS, for which activity and severity seem most significant prior to the fourth decade. The HS literature suggests men have greater disease severity, as assessed by HS scoring instruments. 5, 6 However, our data indicate that an increase in scores among men may result in no greater likelihood of receipt or escalation of treatment. The increased likelihood of receiving and escalating treatment among of patients with HS with subsidized insurance may be reflective of the statewide mandate for health insurance which was commensurate with the establishment of the HS cohort. It is unclear why nonwhites were less likely to receive treatment, although this observation may be more reflective of societal or care disparities rather than differences in disease severity among demographic groups. Receipt and escalation of treatment was also associated with a greater number of physician visits which likely reflects complexity of care related to treatment and perhaps to comorbidities among patients with HS. High frequency of emergency department and inpatient use by these patients is also documented.
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Our data have limitations that warrant caution when interpreting the results. Our cohort is derived from multiple community-based and academic hospitals within a single institution. The institution's race and ethnicity data used in the analysis are self-reported but are not yet structured according to the 2010 US Census Bureau classification for people of Hispanic ethnicity. Although the cohort is highly diversified, it is unclear if patients with HS are representative of those in other parts of the United States or in other countries. As with other studies using a retrospective observational methodology, we could not account for all confounders, nor can the interpretation of the regression analyses be singular.
Conclusions
We have observed course of disease in HS to be progressive. We have identified clinical factors that patients and clinicians may consider in developing partnered short-and longterm treatment strategies. We have also identified factors, namely obesity and male sex, which do not seem to additionally influence treatment of HS.
